In humans, the activation of PPAR-α by fibrate has shown to increase the circulating levels of antiatherosclerotic HDL-cholesterol that lowers TG levels, liberates FA and apolipoprotein CIII (apo-CIII), improves the overall atherogenic plasma lipid profile, and has beneficial effects on inflammation, insulin resistance, and metabolic syndrome. Here, PPARA is linked to Insulin resistance.